Biotron Ltd has released a press release.
Renounceable Issue
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
- Bit225 Covid-19 Human Study Commenced
- BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
- Positive FDA guidance for covid-19 clinical program
- BIT225 effective against established sars-cov-2 in animals
Later from Biotron
- Commencement of Rights Trading - BITRC
- $1.43M R&D rebate received
- International Presentation of BIT225 COVID-19 Data
- Completion of Phase 2 HIV-1 Clinical Trials
- Commencement Phase 2 Covid-19 Clinical Trial
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron